On ECHEMI
Home > Drugs > Lysine aspirin for injection

Lysine aspirin for injection

Function and Efficacy

Overdose of this product (equivalent to more than 5g of aspirin per day) can cause salicylic acid reaction, so the drug should be discontinued immediately and glucose injection containing sodium bicarbonate should be given intravenously to accelerate the excretion of salicylate from urine. Hemodialysis or peritoneal dialysis may be considered for severe overdose; if bleeding occurs, blood transfusion or vitamin K supplementation should be given.

Ingredients

The main ingredients of this product are: Lysine

Name Description Content CAS NO. Manufacturer
DL-Lysine acetylsalicylateIngredients

Overdose of this product (equivalent to more than 5g of aspirin per day) can cause salicylic acid reaction, so the drug should be discontinued immediately and glucose injection containing sodium bicarbonate should be given intravenously to accelerate the excretion of salicylate from urine. Hemodialysis or peritoneal dialysis may be considered for severe overdose; if bleeding occurs, blood transfusion or vitamin K supplementation should be given.

More
62952-06-1 13

Indication

Used for fever and mild to moderate pain.

Usage and Dosage

For intramuscular or intravenous injection, dissolve in 4 ml of water for injection or 0.9% sodium chloride injection and inject. (1) Adults: 0.9-1.8 g at a time, twice a day. (2) Children: 10-25 mg/kg per day, divided into 2 doses.

Adverse Reactions

(1) When used together with any drug that can cause hypoprothrombinemia, thrombocytopenia, decreased platelet aggregation function or bleeding from gastrointestinal ulcers, there is a risk of aggravating coagulation disorders and causing bleeding. (2) When used together with anticoagulants (dicoumarol, heparin, etc.) and thrombolytic drugs (streptokinase, urokinase), there is a risk of increasing bleeding. (3) Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) can increase the excretion of this product in the urine and reduce the blood concentration. However, when the blood concentration of this product has reached a stable state and the alkaline drug is discontinued, the blood concentration of this product can rise to a toxic level. Carbonic anhydrase inhibitors can alkalinize urine, but can cause metabolic acidosis, which can not only reduce the blood concentration, but also increase the amount of this product that penetrates into the brain tissue, thereby increasing toxic reactions. (4) Uric acidifying drugs can reduce the excretion of this product and increase its blood concentration. The addition of uricosuric drugs to patients whose blood drug concentration of this drug is already stable may lead to an increase in the blood drug concentration of this drug and an increase in toxic reactions. (5) Glucocorticoids can increase the excretion of salicylates. In order to maintain the blood drug concentration of this drug when used together, the dose of this drug should be increased if necessary. Long-term use of this drug with glucocorticoids, especially when used in large quantities, increases the risk of gastrointestinal ulcers and bleeding. It is not recommended to use these two types of drugs at the same time. (6) The hypoglycemic effect of insulin or oral hypoglycemic drugs can be enhanced and accelerated by using this drug together. (7) When used together with methotrexate, it can reduce the binding of methotrexate to proteins, reduce its excretion from the kidneys, increase blood drug concentrations and increase toxic reactions. (8) The uricosuric effect of probenecid or sulfinpyrazone can be reduced by using this drug at the same time; when the blood concentration of salicylate is greater than 50μg/ml, it is significantly reduced, and it is even more so when it is greater than 100-150μg/ml. In addition, probenecid can reduce the clearance of salicylates from the kidneys, thereby increasing the latter's blood concentration.

Precautions

It should not be used in the following situations: active peptic ulcer or gastrointestinal bleeding caused by other reasons; hemophilia or thrombocytopenia; those with a history of allergy to aspirin or other non-steroidal anti-inflammatory drugs, especially those with asthma, angioedema or shock.

Drug Interactions

(1) Gastrointestinal reactions: Short-term use has fewer adverse reactions, occasionally with mild gastrointestinal reactions (such as stomach discomfort, nausea, and vomiting). When the dosage is large, severe cases may cause gastrointestinal bleeding. Long-term use has a high incidence of peptic ulcers. (2) Effects on the blood system: This product antagonizes the effect of vitamin K, inhibits the synthesis of prothrombin, and prolongs bleeding time. Vitamin K can be given for prevention and treatment. Long-term use can inhibit platelet aggregation and cause bleeding tendency. (3) Effects on liver and kidney function: Long-term use of this product may cause elevated transaminase, liver cell necrosis, and kidney damage, which can be restored by stopping the drug in time. (4) Salicylic acid reaction: Manifestations include headache, dizziness, tinnitus, decreased vision and hearing, nausea, vomiting, diarrhea, and severe cases may have mental disorders, rapid breathing, acid-base imbalance, bleeding, and even

Storage

Sealed, store in a cool, dry place.

Packaging Specification

0.5g

Manufacturer

Hainan Meimei Xilin Biopharmaceutical Co., Ltd.

  • Founded in:

    2007-12-24
  • Address:

    Factory Building No. 26, Guilinyang Development Zone, Meilan District, Haikou City
  • Tax NO.:

    91460000798744593P
  • Registered Funds:

    10 million yuan
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.